title: Flecainide use in children with cardiomyopathy or structural heart disease.
abstract: Flecainide is frequently used for treatment of cardiac arrhythmias in children. Due to concerns regarding increased mortality, there has been hesitancy to use flecainide in children with congenital heart disease (CHD) or cardiomyopathy (CM). The objective of this study was to describe trends in use of flecainide in children with CHD or CM and assess its association with cardiac arrest or death. Data from 42 children's hospitals contained in the PHIS database (2004-2011) were analyzed. All patients with CHD or CM receiving anti-arrhythmic therapy for supraventricular arrhythmias were reviewed. Trends in flecainide use were analyzed, and the incidence of cardiac arrest or death was compared to patients receiving other anti-arrhythmics. There were 3,544 pts with CHD or CM who received anti-arrhythmic therapy (median age 73 days). Flecainide was administered in 229 pts (6.5%). There was a trend toward increased use of flecainide in this population, increasing from 4.6% in 2004 to 8.7% in 2011 (p = 0.07). The incidence of cardiac arrest in patients with CHD or CM receiving flecainide was 3.0% with an overall mortality of 4.3%. The mortality was 2.9% in pts with CM and nobody with single ventricle physiology died. Based on multivariable analysis, when compared to pts with CHD or CM receiving other anti-arrhythmics, there was no difference in the incidence of cardiac arrest (p = 0.31) or death (p = 0.28). Flecainide use in children with CHD or CM has increased in recent years. The incidence of cardiac arrest or death with flecainide administration in this cohort appears comparable to other anti-arrhythmic agents.
authors.affiliation: Section of Pediatric Cardiology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
authors.forename: Brady S
authors.initials: BS
authors.lastname: Moffett
authors.forename: Santiago O
authors.initials: SO
authors.lastname: Valdes
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Lupo
authors.forename: Caridad
authors.initials: C
authors.lastname: delaUz
authors.forename: Christina
authors.initials: C
authors.lastname: Miyake
authors.forename: Michele
authors.initials: M
authors.lastname: Krenek
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Kim
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005260:Female; D005424:Flecainide / Q000627:therapeutic use*; D006330:Heart Defects, Congenital / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States
chemical_list: D000889:Anti-Arrhythmia Agents; D005424:Flecainide
references.citation: Heart Lung Circ. 2012 Feb;21(2):96-100
references.pmid: 22119737
references.citation: J Am Coll Cardiol. 1991 Aug;18(2):356-65
references.pmid: 1906902
references.citation: Paediatr Drugs. 2000 May-Jun;2(3):171-81
references.pmid: 10937468
references.citation: Am Heart J. 1992 Dec;124(6):1614-21
references.pmid: 1462922
references.citation: Am J Cardiol. 1996 Jan 25;77(3):72A-82A
references.pmid: 8607395
references.citation: Curr Pharm Des. 2008;14(8):766-9
references.pmid: 18393876
references.citation: N Engl J Med. 1989 Aug 10;321(6):406-12
references.pmid: 2473403
references.citation: Pediatr Cardiol. 2013 Feb;34(2):408-14
references.pmid: 22903738
references.citation: Am J Cardiol. 1990 Jan 16;65(4):20B-29B
references.pmid: 2105049
references.citation: J Am Coll Cardiol. 1999 Jun;33(7):2067-72
references.pmid: 10362215
references.citation: N Engl J Med. 1991 Mar 21;324(12):781-8
references.pmid: 1900101